早期胰腺导管腺癌预后十五基因签名数据集

数据集获取（Figshare）

• 源站标题：Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
• DOI：10.1371/journal.pone.0133562
• 发布日期：2015-08-06
• 文件数：12 个
• 文件总体积：1.13 MB
• 源站页面：https://plos.figshare.com/articles/dataset/_Prognostic_Fifteen_Gene_Signature_for_Early_Stage_Pancreatic_Ductal_Adenocarcinoma_/1504834

命令行下载

curl -L -o "S1_Fig.pdf" "https://ndownloader.figshare.com/files/2204268"
curl -L -o "S2_Fig.pdf" "https://ndownloader.figshare.com/files/2204269"
curl -L -o "S3_Fig.pdf" "https://ndownloader.figshare.com/files/2204270"
curl -L -o "S4_Fig.pdf" "https://ndownloader.figshare.com/files/2204272"
curl -L -o "S5_Fig.pdf" "https://ndownloader.figshare.com/files/2204273"
curl -L -o "S1_Table.pdf" "https://ndownloader.figshare.com/files/2204274"
curl -L -o "S2_Table.pdf" "https://ndownloader.figshare.com/files/2204275"
curl -L -o "S3_Table.pdf" "https://ndownloader.figshare.com/files/2204276"

文件清单

• S1_Fig.pdf（40.93 KB）
• S2_Fig.pdf（25.02 KB）
• S3_Fig.pdf（49.63 KB）
• S4_Fig.pdf（153.84 KB）
• S5_Fig.pdf（176.34 KB）
• S1_Table.pdf（5.40 KB）
• S2_Table.pdf（8.51 KB）
• S3_Table.pdf（13.54 KB）
• S4_Table.pdf（82.42 KB）
• S5_Table.pdf（5.04 KB）
• S6_Table.pdf（100.42 KB）
• S7_Table.pdf（467.01 KB）

文件总体积 1.13 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

The outcomes of patients treated with surgery for early stage pancreatic ductal adenocarcinoma (PDAC) are variable with median survival ranging from 6 months to more than 5 years. This challenge underscores an unmet need for developing personalized medicine strategies to refine the current treatment decision-making process. To derive a prognostic gene signature for patients with early stage PDAC, a PDAC cohort from Moffitt Cancer Center (n = 63) was used with overall survival (OS) as the primary endpoint. This was further evaluated using an independent microarray cohort dataset (Stratford et al: n = 102). Technical validation was performed by NanoString platform. A prognostic 15-gene signature was developed and showed a statistically significant association with OS in the Moffitt cohort (hazard ratio [HR] = 3.26; p<0.001) and Stratford et al cohort (HR = 2.07; p = 0.02), and was independent of other prognostic variables. Moreover, integration of the signature with the TNM staging system improved risk prediction (p<0.01 in both cohorts). In addition, NanoString validation showed that the signature was robust with a high degree of reproducibility and the association with OS remained significant in the two cohorts. The gene signature could be a potential prognostic tool to allow risk-adapted stratification of PDAC patients into personalized treatment protocols; possibly improving the currently poor clinical outcomes of these patients.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0133562（source: https://plos.figshare.com/articles/dataset/_Prognostic_Fifteen_Gene_Signature_for_Early_Stage_Pancreatic_Ductal_Adenocarcinoma_/1504834）。